Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01303575
Other study ID # 5U48DP001949
Secondary ID
Status Completed
Phase N/A
First received February 18, 2011
Last updated June 22, 2015
Start date September 2010
Est. completion date January 2015

Study information

Verified date November 2013
Source The University of Texas Health Science Center, Houston
Contact n/a
Is FDA regulated No
Health authority United States: Institutional Review Board
Study type Interventional

Clinical Trial Summary

This study will evaluate the effect of an American Indian/Alaska Native (AI/AN) adaptation of the It's Your Game…Keep It Real (IYG) intervention, relative to a comparison condition on sexual behavior outcomes and psychosocial variables for middle school aged youth (12 - 14 years old). The original IYG program was designed for students in Houston middle schools to help students delay sexual initiation and if sexually active, use condoms and contraception. The present study will adapt the existing IYG program for an AI/AN youth cohort; the original IYG curriculum will be transferred into a web-based format and modified to incorporate additional culturally-relevant components. The primary hypothesis to be tested is: (1) students who receive the web-based curriculum will delay sexual activity relative to those who receive standard care. The major dependent variable is the proportion of students initiating sexual activity. Secondary hypotheses will examine the effect of the web-based curriculum on specific types of sex and psychosocial variables related to sexual risk-taking behavior. This project will also examine the effect of the intervention on the proportion of students who are sexually active, number of times students engage in unprotected sexual intercourse, and students' number of sexual partners.


Description:

The goal of this four year research project is to adapt and evaluate the effectiveness of an Internet-based HIV/STI, and pregnancy prevention curriculum for American Indian/Alaska Native (AI/AN) middle school-aged youth (12-14 years). This curriculum will be adapted from a successful, Internet-accessible, prevention program, It's Your Game…Keep it Real (IYG).

During year 1 (Fall 2010 through Spring 2011) of this project, the study team will test the usability of the existing IYG program, while performing an assessment of existing programs for cultural of the IYG intervention. In year 2 (beginning Fall 2011), the project team plans to initiate and complete development of the cultural-adapted IYG intervention for AI/AN youth (IYG-AI/AN). Starting in year 3 (Fall 2012), the study efficacy trial will commence to evaluate the effectiveness of IYG-AI/AN on sexual behaviors and psychosocial determinants of those behaviors among AI/AN youth in three regions (Alaska, the Pacific Northwest, including Idaho, Oregon, and Washington state, and Arizona) relative to a comparison condition. Recruitment sites will be middle schools and Boys and Girls Clubs (BGCs), identified through their affiliations with the Alaska Native Tribal Health Consortium (ANTHC), the Pacific Northwest Tribal Epicenter (the Epicenter) and the Inter Tribal Council of Arizona (ITCA). Randomization will occur regionally, at the site (schools and BGCs) level, to one of two conditions: IYG-AI/AN and a comparison condition. The comparison condition will consist of two web-based educational programs unrelated to sexual health. The IYG-AI/AN intervention will be compared against the comparison condition. The efficacy trial will continue for 16 months into year 4 (2013).

The primary hypothesis to be tested is: (1) youth who receive the IYG-AI/AN intervention will delay sexual activity relative to those who receive the comparison condition. The major dependent variable is the proportion of AI/AN youth initiating sexual activity (vaginal, oral, or anal sex). Secondary hypotheses will examine the effect of the intervention on specific types of sex (e.g., vaginal, oral, anal) and psychosocial variables such as youth intentions, knowledge, self-efficacy, attitudes, and perceived norms related to sexual risk-taking behavior. Secondary hypotheses will also examine the effect of the intervention on the proportion of AI/AN youth who are sexually active, occurrences of unprotected sexual intercourse and the number of sexual partners among these AI/AN youth.


Recruitment information / eligibility

Status Completed
Enrollment 574
Est. completion date January 2015
Est. primary completion date January 2015
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Both
Age group 12 Years to 14 Years
Eligibility Inclusion Criteria:

- American Indian or Alaska Native descent and/or tribal affiliation

- Youth ages 12-14 attending regular classes in regional middle schools or youth attending after-school programs and/or Boys and Girls Clubs

- English-speaking

Exclusion Criteria:

- Youth who are not of American Indian or Alaska Native descent

- Any physical or mental condition that would inhibit the ability to complete surveys and use computer programs, such as cognitive impairment, motor disorders (e.g. quadriplegia), learning difficulties or psychiatric/behavioral problems (e.g. autism, attention deficit disorder)

- Students will be informed that the surveys and intervention materials will only be available in English and will be asked to consider their comfort level with participating in the study

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention


Related Conditions & MeSH terms


Intervention

Behavioral:
HIV, STI and Pregnancy Prevention Curriculum
A complete internet-based, "It's Your Game...Keep It Real" Intervention Program
Control Curricula
A computer-based, science education program that does not contain elements of sexual health education

Locations

Country Name City State
United States Alaska Native Tribal Health Consortium Anchorage Alaska
United States University of Texas Health Science Center, Houston Houston Texas
United States Inter Tribal Council of Arizona, Inc. Phoenix Arizona
United States Northwest Portland Area Indian Health Board Portland Oregon

Sponsors (4)

Lead Sponsor Collaborator
The University of Texas Health Science Center, Houston Alaska Native Tribal Health Consortium, Inter Tribal Council of Arizona, Northwest Portland Area Indian Health Board

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Delay onset of sexual activity delay onset of vaginal, oral or anal sex baseline No
Primary Delay onset of sexual activity delay onset of vaginal, oral or anal sex 5-months No
Primary Delay onset of sexual activity delay onset of vaginal, oral or anal sex 16-months No
Secondary Reduce alcohol/drug use baseline No
Secondary Reduce instances of sexual activity baseline No
Secondary Decrease the number of sexual partners baseline No
Secondary Condom use during sexual activity baseline No
Secondary Contraceptive use while sexually active baseline No
Secondary Prevalence of sexually transmitted infections baseline No
Secondary Increase sexual knowledge baseline No
Secondary Changes in sexual beliefs baseline No
Secondary Changes in attitudes toward sexual activity baseline No
Secondary Changes in perception of sexual beliefs among peers baseline No
Secondary Increased self-efficacy for refusal skills baseline No
Secondary Increased self-efficacy for condom use baseline No
Secondary Increased avoidance of risky situations baseline No
Secondary Changes in perceived norms about sexual activity baseline No
Secondary Changes in reasons for or against having sex baseline No
Secondary Changes in intentions to have/abstain from sex baseline No
Secondary Reduce alcohol/drug use 5-months No
Secondary Reduce alcohol/drug use 16-months No
Secondary Reduce instances of sexual activity 5-months No
Secondary Reduce instances of sexual activity 16-months No
Secondary Decrease the number of sexual partners 5-months No
Secondary Decrease the number of sexual partners 16-months No
Secondary Condom use during sexual activity 5-months No
Secondary Condom use during sexual activity 16-months No
Secondary Contraceptive use while sexually active 5-months No
Secondary Prevalence of sexually transmitted infections 5-months No
Secondary Prevalence of sexually transmitted infections 16-months No
Secondary Increase sexual knowledge 5-months No
Secondary Increase sexual knowledge 16-months No
Secondary Changes in sexual beliefs 5-months No
Secondary Changes in sexual beliefs 16-months No
Secondary Changes in attitudes toward sexual activity 5-months No
Secondary Changes in attitudes toward sexual activity 16-months No
Secondary Changes in perception of sexual beliefs among peers 5-months No
Secondary Changes in perception of sexual beliefs among peers 16-months No
Secondary Increased self-efficacy for refusal skills 5-months No
Secondary Increased self-efficacy for refusal skills 16-months No
Secondary Increased self-efficacy for condom use 5-months No
Secondary Increased self-efficacy for condom use 16-months No
Secondary Increased avoidance of risky situations 5-months No
Secondary Increased avoidance of risky situations 16-months No
Secondary Changes in perceived norms about sexual activity 5-months No
Secondary Changes in perceived norms about sexual activity 16-months No
Secondary Changes in reasons for or against having sex 5-months No
Secondary Changes in reasons for or against having sex 16-months No
Secondary Changes in intentions to have/abstain from sex 5-months No
Secondary Changes in intentions to have/abstain from sex 16-months No
See also
  Status Clinical Trial Phase
Completed NCT05454514 - Automated Medication Platform With Video Observation and Facial Recognition to Improve Adherence to Antiretroviral Therapy in Patients With HIV/AIDS N/A
Completed NCT03760458 - The Pharmacokinetics, Safety, and Tolerability of Abacavir/Dolutegravir/Lamivudine Dispersible and Immediate Release Tablets in HIV-1-Infected Children Less Than 12 Years of Age Phase 1/Phase 2
Completed NCT03141918 - Effect of Supplementation of Bioactive Compounds on the Energy Metabolism of People Living With HIV / AIDS N/A
Completed NCT03067285 - A Phase IV, Open-label, Randomised, Pilot Clinical Trial Designed to Evaluate the Potential Neurotoxicity of Dolutegravir/Lamivudine/Abacavir in Neurosymptomatic HIV Patients and Its Reversibility After Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide. DREAM Study Phase 4
Recruiting NCT04579146 - Coronary Artery Disease (CAD) in Patients HIV-infected
Completed NCT06212531 - Papuan Indigenous Model of Male Circumcision N/A
Active, not recruiting NCT03256422 - Antiretroviral Treatment Taken 4 Days Per Week Versus Continuous Therapy 7/7 Days Per Week in HIV-1 Infected Patients Phase 3
Completed NCT03256435 - Retention in PrEP Care for African American MSM in Mississippi N/A
Completed NCT00517803 - Micronutrient Supplemented Probiotic Yogurt for HIV/AIDS and Other Immunodeficiencies N/A
Active, not recruiting NCT03572335 - Systems Biology of Diffusion Impairment in Human Immunodeficiency Virus (HIV)
Completed NCT04165200 - Fecal Microbiota Transplantation as a Therapeutic Strategy for Patients Infected With HIV N/A
Recruiting NCT03854630 - Hepatitis B Virus Vaccination in HIV-positive Patients and Individuals at High Risk for HIV Infection Phase 4
Terminated NCT03275571 - HIV, Computerized Depression Therapy & Cognition N/A
Completed NCT02234882 - Study on Pharmacokinetics Phase 1
Completed NCT01618305 - Evaluating the Response to Two Antiretroviral Medication Regimens in HIV-Infected Pregnant Women, Who Begin Antiretroviral Therapy Between 20 and 36 Weeks of Pregnancy, for the Prevention of Mother-to-Child Transmission Phase 4
Recruiting NCT05043129 - Safety and Immune Response of COVID-19 Vaccination in Patients With HIV Infection
Not yet recruiting NCT05536466 - The Influence of Having Bariatric Surgery on the Pharmacokinetics, Safety and Efficacy of the Novel Non-nucleoside Reverse Transcriptase Inhibitor Doravirine N/A
Recruiting NCT04985760 - Evaluation of Trimer 4571 Therapeutic Vaccination in Adults Living With HIV on Suppressive Antiretroviral Therapy Phase 1
Completed NCT05916989 - Stimulant Use and Methylation in HIV
Terminated NCT02116660 - Evaluation of Renal Function, Efficacy, and Safety When Switching From Tenofovir/Emtricitabine Plus a Protease Inhibitor/Ritonavir, to a Combination of Raltegravir (MK-0518) Plus Nevirapine Plus Lamivudine in HIV-1 Participants With Suppressed Viremia and Impaired Renal Function (MK-0518-284) Phase 2